Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
it slots into tyrosinase, or the key enzyme that your skin uses to make melanin), and competitively blocks it so your skin produces less pigment over time
Benefits of Glutathione Treatments Glutathione treatments are popular for both wellness and appearance goals
There is a growing body of research on BPC-157 and Thymosin Beta 4, but long-term studies and large-scale clinical trials are still lacking
